Jeffrey Walsh

Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA.

Part of Novartis AG, PathoGenesis Corp is a company that develops and markets innovative treatments for chronic infectious diseases. The company is based in Seattle, WA. The company was founded by Isaac Blech. PathoGenesis was acquired by Chiron Corp. on September 19, 2000 for $639.75 million.

Allscripts LLC provides clinical software solutions. It offers point-of-care decision support solutions, document imaging solutions and the resale of related hardware. The company was founded in 2001 and is headquartered in Chicago, IL.

Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.